OnVagus received approval to begin the first human trial of its noninvasive vagus nerve-stimulation device for cancer-related wasting at MD Anderson Cancer Center. The study marks an early translational step toward modulating neuroimmune and appetite-related pathways without implanted hardware. Cancer cachexia remains a major unmet need, where limited therapies and the systemic nature of the disorder complicate treatment. A noninvasive approach could shift the feasibility and adoption profile if early safety and biologic effect endpoints are supported. Trial design details—stimulation parameters, patient selection, and outcome measures like weight loss, function, and inflammatory markers—will be closely watched in subsequent readouts.